Skip to main content

Regulatory Considerations for Manufacturing and Delivery of Cell-based Therapies for Cardiovascular Indications

Journal of Cardiovascular Translational Research volume 1, Article number: 196 (2008) Cite this article

Abstract

Developers of cell-based therapies intended for the treatment of cardiovascular indications must address a number of regulatory issues related to the manufacturing and delivery of living cell products to patients. This article highlights issues that must be considered regarding the cell and tissue source and ancillary materials, the development of a regulatory acceptable manufacturing process, the importance of product characterization as a measure of product quality and clinical site logistics for handling and storing living cell products. Finally, regulatory issues regarding the various delivery systems commonly used for delivery cells to cardiac tissues are touched upon.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. US Food and Drug Administration. (2004). Biologics Response Modifiers Advisory Committee. Cellular products for the treatment of cardiac disease, FDA briefing document. 2004 Mar 18. Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/4018b1.htm

  2. Areman, E. M., Benton, K., & McFarland, R. (2006). Regulatory considerations in manufacturing, product testing and preclinical development of cellular products for cardiac repair. In N. Dib, D. A. Taylor, & E. B. Diethrich (Eds.), Stem cell therapy and tissue engineering for cardiovascular repair. New York, NY: Springer.

    Google Scholar 

  3. US Food and Drug Administration. (2008). Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs).

  4. US Food and Drug Administration. (2007). Draft Guidance for Industry: Cell Selection Devices for Point of Care Production of Minimally Manipulated Autologous Peripheral Blood Stem Cells (PBSCs).

  5. Weber, D. J. (2006). Manufacturing considerations for clinical uses of therapies derived from stem cells. Methods Enzymology, 420, 410–430.

    Article  CAS  Google Scholar 

  6. United States Pharmacopoeia. (2006).<1043>Ancillary Materials for Cell, Gene, and Tissue engineered Therapy Products. USP 29–NF 24.

  7. US Food and Drug Administration. (2006). Cellular, Tissue and Gene Therapies Advisory Committee. Potency Measurements for Cellular and Gene Therapy Products. FDA briefing document. 2006 Feb. 09–10. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006–4205B1-index.htm.

Download references

Author information

Affiliations

  1. The Biologics Consulting Group, Inc., 7117 58th Avenue, N.E., Seattle, WA, 98115, USA

    Darin J. Weber

Authors
  1. Darin J. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darin J. Weber.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Weber, D.J. Regulatory Considerations for Manufacturing and Delivery of Cell-based Therapies for Cardiovascular Indications. J. of Cardiovasc. Trans. Res. 1, 196 (2008). https://doi.org/10.1007/s12265-008-9036-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12265-008-9036-y

Keywords

  • Food and Drug Administration
  • FDA
  • Cellular Therapy
  • Product Development
  • Regulatory
  • Manufacturing